NT-PROBNP PREDICTS RECURRENCE AFTER CATHETER ABLATION IN A HYPERTENSIVE POPULATION UNDERGOING AGGRESSIVE BLOOD PRESSURE MANAGEMENT: A SUB-STUDY OF SMAC-AF

Radiofrequency catheter ablation for atrial fibrillation (AF) has developed into a mainstay therapy. The recent Substrate Modification with Aggressive Blood Pressure Control (SMAC-AF) randomized controlled trial did not find that reducing blood pressure prior to ablation reduced recurrence of AF. There has been developing interest in NT-proBNP being a biomarker that could predict ablation success. We investigated the effect of baseline NT-proBNP...